Aduro Clean Technologies Inc. (ADUR) confirmed that its Hydrochemolytic™ Technology (HCT) can be applied to highly paraffinic crude oils, a feedstock that represents 20‑33 % of global production. Bench‑scale experiments using yellow and black wax samples from the Uinta Basin in Utah showed that HCT reduces wax content and produces lighter, transport‑ready crude, potentially lowering the need for heated logistics and expanding market access for these otherwise constrained feedstocks.
The company filed a continuation‑in‑part (CIP) patent application with the U.S. Patent and Trademark Office, extending its existing portfolio that previously covered bitumen upgrading and plastic recycling. The filing protects the new paraffinic crude application and signals Aduro’s commitment to securing intellectual property around its versatile platform.
"Our work with paraffinic crude oils builds on what we have established in bitumen upgrading and the chemical recycling of waste plastics. Through bench‑scale evaluation of multiple wax‑rich samples, we have confirmed that Hydrochemolytic™ Technology can be applied to long‑chain paraffinic structures, supporting new pathways for improving both handling and market access," said CEO Ofer Vicus. Vicus added that the company “continues to advance our Hydrochemolytic™ Technology platform through targeted applications that address real global challenges in the energy and materials sectors.”
The Uinta Basin’s paraffinic crudes are prized for low sulfur, metals, and nitrogen, but their high wax content forces producers to use heated pipelines and specialized storage, which drives up transportation costs. By lowering wax levels, HCT could reduce these costs and unlock higher prices for the crude, creating a new revenue stream for Aduro’s platform and positioning the company to serve a substantial portion of the world’s oil supply.
Beyond the new application, Aduro has moved its Next Generation Process (NGP) pilot plant into operating campaigns and is progressing on its First‑of‑a‑Kind industrial facility in Chemelot, Netherlands. The company’s cash position rose to $39.42 million as of February 28 2026, up from $6.96 million in Q4 2025, providing financial flexibility to pursue further scale‑up and commercialization of HCT across multiple feedstocks.
revised_sentiment_rating":2} }
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.